Dapagliflozin in PRESERVED Ejection Fraction Heart Failure (PRESERVED-HF)
The major goal of this study is to see how dapagliflozin affects heart failure, disease-specific biomarkers, symptoms, health status, and quality of life in patients with chronic heart failure with retained systolic function when compared to placebo.
Description in detail:
The impact of once-daily dapagliflozin 10 mg on heart failure disease-specific biomarkers (NTproBNP and BNP), symptoms, health status, and quality of life in patients with chronic heart failure with maintained systolic function in a 12-week randomized, double-blind, placebo-controlled trial. The effects of dapagliflozin vs. placebo on various echocardiographic parameters will also be investigated in an imaging substudy.